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ABSTRACT 
 
Fatty acid synthase (FASN) is a key lipogenic enzyme for de novo fatty acid 
biosynthesis and a druggable metabolic oncoprotein that is activated in most human 
cancers. We evaluated whether the HER2-driven lipogenic phenotype might 
represent a biomarker for sensitivity to pharmacological FASN blockade. A majority 
of clinically HER2-positive tumors were scored as FASN overexpressors in a series 
of almost 200 patients with invasive breast carcinoma. Re-classification of HER2-
positive breast tumors based on FASN gene expression predicted a significantly 
inferior relapse-free and distant metastasis-free survival in HER2+/FASN+ patients. 
Notably, non-tumorigenic MCF10A breast epithelial cells engineered to overexpress 
HER2 upregulated FASN gene expression, and the FASN inhibitor C75 abolished 
HER2-induced anchorage-independent growth and survival. Furthermore, in the 
presence of high concentrations of C75, HER2-negative MCF-7 breast cancer cells 
overexpressing HER2 (MCF-7/HER2) had significantly higher levels of apoptosis 
than HER2-negative cells. Finally, C75 at non-cytotoxic concentrations significantly 
reduced the capacity of MCF-7/HER2 cells to form mammospheres, an in vitro 
indicator of cancer stem-like cells. Collectively, our findings strongly suggest that 
the HER2-FASN lipogenic axis delineates a group of breast cancer patients that 
might benefit from treatment with therapeutic regimens containing FASN inhibitors.  
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INTRODUCTION 
 
The up-regulation of fatty acid synthase (FASN), a key lipogenic enzyme in de novo 
biogenesis of fatty acids, appears to necessarily accompany the natural history of 
most human cancers (Menendez and Lupu, 2007). FASN-driven endogenous 
lipogenesis confers growth and survival advantages to cancer cells (Menendez and 
Lupu, 2004, 2006; Menendez, 2010), and FASN signaling regulates well-
established cancer-controlling networks (Menendez et al., 2004a, b; Lupu and 
Menendez, 2006; Vazquez-Martin et al., 2009). Indeed, the discovery that sole 
overexpression of FASN induces a transformation-like phenotype in epithelial cells 
(Vazquez-Martin et al., 2008; Migita et al., 2009) has led to the suggestion that 
FASN operates as a bona fide oncogene (Baron et al., 2004; Menendez and Lupu, 
2006; Patel et al., 2015).  
 
Increasing experimental evidence for a metabolo-oncogenic role of FASN in human 
carcinomas and their precursor lesions implies that pharmacological targeting of 
FASN might offer new therapeutic options for metabolically preventing and/or 
treating cancer. Consequently, a variety of FASN inhibitors have been developed in 
recent years. Among them is the natural product cerulenin and its semi-synthetic 
derivative C75 (α-methylene-γ-butyrolactone), and C93, C247 and FAS31, which 
were developed in an effort to overcome the lack of potency of C75 and its 
undesirable side-effects (Alli et al., 2005; Orita et al., 2007). Orlistat, an FDA-
approved pancreatic lipase inhibitor, was originally developed as an anti-obesity 
drug (Kridel et al., 20014; Menendez et al., 2005a). Additionally, the anti-microbial 
agent triclosan (Sadowski et al., 2014) and the dibenzenesulfonamide urea 
GSK837149A (Vázquez et al., 2008) have consistently demonstrated preclinical 
activity in cultured cancer cell lines and xenograft models (reviewed in Lupu and 
Menendez, 2006b; Flavin et al., 2010; Pandey et al., 2012). Although none of these 
compounds have been tested in cancer patients because of limitations imparted by 
their pharmacological properties (e.g., poor cell permeability, poor oral 
bioavailability and lack of selectivity) or side-effect profiles (e.g., anorexia and 
weight-loss), which could be limiting in the development of cancer therapy, a new 
generation of FASN inhibitors have only just entered the clinic (Arkenau et al., 2015; 
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O’Farrell et al., 2015; Patel et al., 2015). Therefore, it will be important to not only 
monitor the levels at which the FASN target is inhibited, but also to effectively select 
patients who are likely to benefit, which could assist in prioritizing the yet-scarce 
anti-FASN drug discovery resources (Jones and Infante, 2015).  
 
Previous studies from our laboratory suggested a strong correlation between the 
sensitivity of breast cancer cell lines to pharmacological FASN blockade and the 
expression of the HER2 oncogene (Menendez et al., 2004a, c, 2005b). To validate 
the HER2-driven lipogenic phenotype as a phenotypic biomarker of sensitivity to 
FASN inhibition, we investigated the clinical and therapeutic relevance of FASN 
expression and activity in HER2-overexpressing breast carcinomas. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HI
ST
OL
OG
Y 
AN
D 
HI
ST
OP
AT
HO
LO
GY
 
(no
n-e
dit
ed
 m
an
us
cri
pt)
 5 
RESULTS 
 
FASN overexpression is frequent in HER2-positive breast carcinomas. Breast 
cancer tissue sections of 189 patients with primary invasive breast carcinomas 
(Menendez et al., 2006) were evaluated for the expression of HER2 and FASN by 
immunohistochemistry. Representative examples of invasive breast carcinomas 
expressing different levels of FASN immunostaining are shown in Fig. 1. Sixty 
(32%) tumors were HER2-positive and 113 tumors (60%) were classified as FASN 
overexpressors (Fig. 1). The majority of clinically HER2-positive tumors (85%) were 
scored as FASN overexpressors, with the remaining 15% classified as negative or 
low-to-moderate FASN expressors. By contrast, an almost identical distribution of 
FASN-overexpressors (48%) and non-FASN overexpressors (52%) was observed 
in clinically HER2-negative tumors. A significant association between HER2- and 
FASN-overexpression was found by Chi-square test (P<0.001).  
 
FASN overexpression confers poor prognosis in HER2-positive breast 
tumors. The close relationship between FASN overexpression and clinical status of 
HER2 expression prompted us to investigate whether FASN might confer clinical 
aggressiveness and, therefore, more adverse prognoses in HER2-positive breast 
carcinomas. We utilized the on-line Kaplan-Meier plotter (http://kmplot.com/; Gyorffy 
et al., 2010) to evaluate whether the re-classification of HER2-positive tumors by 
the median expression of the FASN gene (217006_x_at) using the best performing 
threshold as a cutoff (Mihály et al., 2013), was sufficient to predict significantly 
different relapse-free survival (RFS) and distant metastasis-free survival (DMSF) 
outcomes.  
 
We assessed the clinical impact of high-FASN expression on RFS and DMSF 
through the molecularly distinct intrinsic subtypes of breast cancer (Mihály and 
Győrffy, 2013), which were classified based on 2013 St. Gallen criteria using the 
expression of HER2, estrogen receptor (ESR1), and Ki67 (MKI67), i.e., luminal A 
(ESR1+, HER2-, MKI67 low), luminal B (ESR+, HER2-, MKI67 high), basal (ESR-, 
HER2-), and HER2+ (HER2+, ESR1-). High-FASN expression was found to 
significantly worsen the RFS (Fig. 2) and DMFS (Fig. 3) of HER2+ breast tumors 
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(HR=1.95; p=0.0037 and HR=2.19; p=0.036, respectively). FASN expression, 
however, failed to distinguish good- and bad-prognoses in other breast cancer 
subtypes, including the intrinsically aggressive basal-like breast carcinomas (Fig. 
3).  
 
FASN inhibition suppresses HER2-induced oncogenic properties in breast 
epithelial cells. To evaluate the biological consequences of FASN activation on 
HER2-driven breast tumor development we utilized MCF10A cells, which are a 
useful in vitro model to analyze the transforming effects of HER2 overexpression 
(Ciardiello et al., 1992; Giunciuglio et al., 1995) as they are dependent on EGF and 
express very low levels of HER1, HER2, and HER3. Consequently, the 
overexpression of HER2 in MCF10A cells recapitulates the common clinical HER1- 
and HER2-positive breast cancer phenotype.  
 
MCF10A cells engineered to stably overexpress HER2 (Menendez et al., 2015) 
were transiently transfected with a luciferase reporter containing a 178-bp FASN 
promoter (FASN-Luc) harboring all the elements necessary for high level 
expression in cancer cells (Swinnen et al., 1997), including a complex SREBP-
binding site. MCF10A/HER2 cells transfected with FASN-Luc had a >2-fold-increase 
in luciferase activity relative to equivalent HER2-negative MCF10A cells when 
grown under standard culture conditions (Fig. 4 left panel). Upon EGF stimulation, 
which recapitulates the paracrine/autocrine stimulation of HER receptor-driven 
signaling, FASN-Luc promoter activity was 3.5-fold higher in MCF10A/HER2 cells 
than in HER2-negative MCF10A cells (Fig. 4, left panel). Immunoblotting analyses 
confirmed that protein level of FASN was significantly increased in MCF10A/HER2 
cells (data not shown). 
 
MCF10A cells are unable to grow in an anchorage-independent fashion in the 
absence of oncogenic stimuli. HER2 overexpression confers anchorage 
independence, which recapitulates an in vivo transformed phenotype that strongly 
correlates with in vivo tumorigenicity. To evaluate a role for the lipogenic activity of 
FASN in HER2-promoted anchorage-independence, cell growth and survival in soft 
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agar were assessed in the presence of C75, a slow-binding FASN inhibitor. 
MCF10A/HER2 colony formation was significantly impaired by C75 treatment at 5 
µg/mL and was completely abolished at 10 µg/mL (Fig. 4, right panel).     
 
FASN-overexpressing, HER2-positive breast cancer cells are exquisitely 
sensitive to FASN inhibition-induced apoptotic cell death. Given the critical role 
of FASN activity in the transforming capability of HER2, we questioned whether 
HER2-overexpressing breast cancer cells might exhibit an increased sensitivity to 
FASN inhibition. We utilized MCF-7 breast cancer cells engineered to stably 
overexpress HER2 (MCF-7/HER2) and which have been shown to have functional 
levels of HER2 comparable with those of HER2 gene-amplified BT-474 breast 
cancer cells (Benz et al., 1992). Our previous results showed that forced expression 
of HER2 in MCF-7 breast cancer cells, which naturally express moderate levels of 
FASN and HER2 (Menendez et al., 2004a), results in a significant enhancement in 
FASN-Luc reporter activity and significant up-regulation of FASN protein relative to 
MCF-7/Neo isogenic controls (Menendez et al., 2005a,c). The half-maximal 
inhibitory concentration (IC50) of C75 was 3.5±1.0 µg/mL in MCF-7/HER2 cells 
measured by MTT reduction and 10.0±1.8 µg/mL in MCF-/Neo cells (Fig. 5, top 
panels).  
 
Although the approximate 3-fold reduction in the IC50 value of C75 strongly 
suggested an exquisite sensitivity of MCF-7/HER2 cells to the FASN inhibitor, it is 
accepted that cell viability assays are often a measure of cellular metabolic activity 
and may not necessarily reflect bona fide cytotoxic effects. We therefore assessed 
whether the differential effects of C75 were due to cell death rather than alterations 
in NAD+ and/or ATP-generating metabolic processes. To do this, we examined the 
effects of C75 on cell cycle progression. Using flow cytometry analysis, we found 
that exposure of MCF-7/Neo control cells to 10 µg/mL C75 resulted in a significant 
increase in G2/M phase cells concomitant with a decrease in the G0/G1 phase (Fig. 
5, bottom panels); however, we failed to detect an increase in cell death (Table 1). 
By contrast, exposure of MCF-7/HER2 cells to 10 µg/mL C75 substantially 
increased cell death as demonstrated by the strong accumulation of a sub-G1 
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population with <2n DNA (57% in MCF-7/HER2 cells versus 12% in MCF-7/Neo 
cells) representing dead cells (Fig. 5, bottom panels; Table 1).  
 
To further confirm that pharmacological inhibition of FASN activity differentially 
promotes cell death in HER2+/FASN+ breast cancer cells, we compared the 
number of sub-G1 hypodiploid cells after treatment with C75 in two models of breast 
cancer cells that either do not express HER2 (e.g., MDA-MB-231) or naturally 
amplify the HER2 oncogene (e.g., BT-474) (Fig. 6, top panel). Whereas a modest 
increase in sub-G1 apoptotic cells was observed in C75-treated HER2-/FASN- 
MDA-MB-231 cells, a dramatic ~20-fold-increase in the number of sub-G1 
hypodiploid cells was observed after C75 treatment of HER2+/FASN+ BT-474 cells 
(Fig. 6, bottom panel). These results not only confirm that C75 regulates cell cycle 
progression without significantly affecting cell death in HER2-negative breast cancer 
cells, but also validate the exquisite sensitivity of HER2-positive cells to FASN 
blockade. 
 
Specific pharmacological inhibition of FASN activity suppresses the HER2-
enhanced formation of cancer stem cell-like cells. The HER2 oncogene plays a 
key role in the generation and maintenance of so-called cancer stem cells (CSC) 
during tumor formation and progression (Korkaya et al., 2008; Martin-Castillo et al., 
2015). Given this and th  increasing evidence suggesting that metabolic 
reprogramming controls the ability of CSCs to resist cancer therapies and promote 
cancer recurrence (Corominas-Faja et al., 2015; Menendez, 2015; Menendez and 
Alarcón, 2014; Menendez et al., 2013, 2014, 2016), we explored whether FASN 
activity might have an impact on the occurrence of CSC-like cellular states in HER2-
positive breast cancer cells by culturing cells in suspension to generate 
mammospheres. As anticipated, MCF-7/HER2 cells formed significantly more 
mammospheres than MCF-7 cells (3.0 ± 0.4% versus 1.9 ± 0.2%), reflecting the 
recognized ability of HER2 to expand the breast CSC population (Korkaya et al., 
2008; Corominas-Faja et al., 2014). To ensure that any C75-induced change in 
mammosphere formation was not related to non-specific toxicity, C75 was used at 
concentrations (0.1 and 1 µg/mL) that did not significantly affect cell viability in 
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monolayer cultures. C75 at 1 µg/mL, but not at 0.1 µg/mL, significantly reduced 
mammosphere formation by approximately 40% in MCF-7 cells (Fig. 7). By 
contrast, the enhanced spheroid formation ability of MCF-7/HER2 cells was 
severely and dose-dependently reduced by C75; the highest dose of C75 (1 
µg/mL) elicited inhibitory effects of ∼80% relative to the basal mammosphere 
forming efficiency found in untreated cultures.  
 
Racemic mixtures of C75 have been used in all previous studies and different 
biological activities of C75 enantiomers have been described, i.e., (+)-C75 inhibits 
carnitine palmitoyltransferase (CPT I), the main regulatory enzyme involved in fatty 
acid oxidation, and accounts for the central anorectic effects of C75 (Bentebibel et 
al., 2006; Mera et al., 2009; Makowski et al., 2013), whereas (-)-C75 specifically 
inhibits FASN activity without affecting CPT I-related food consumption (Makoswski 
et al., 2013). Because of this, we finally determined whether treatment with the (-)-
C75 enantiomer was sufficient to recapitulate the suppressive effects of C75 on 
self-renewal of HER2-driven CSC-like cell populations. Remarkably, MCF-7/HER2 
cells required a 10-fold lower concentration of the FASN-specific (-)-C75 enantiomer 
than MCF-7/Neo cells to decrease mammosphere-forming efficiency by 50% (Fig. 
7), confirming that the C75-driven suppression of HER2-enhanced formation of 
CSC-like cells was due to its ability to inhibit FASN activity.  
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DISCUSSION 
 
Our results support the hypothesis that the metabolic oncogene FASN plays an 
important role in HER2-driven breast cancer progression and may be a novel 
therapeutic target in HER2-overexpressing breast carcinomas. 
 
Immunohistochemical staining for FASN in almost 200 cases of invasive ductal 
breast carcinoma confirmed a significant positive correlation with HER2 status. 
These findings are consistent with recent studies showing a strong correlation 
between FASN and HER2 gene amplification: FASN expression was highest in 
immunohistochemically HER2+ tumors and lowest in triple-negative breast 
carcinomas (Yang et al., 2013; Jung et al., 2015; Kim et al., 2015). 
 
Our results show that different breast cancer subtypes varyingly employ cancer-
associated metabolic pathways such as the FASN-driven lipogenic phenotype. 
Perhaps more importantly, the differential usage of the FASN-driven lipogenic 
phenotype seems to have clinical implications for different breast cancer subtypes. 
Specifically, whereas FASN-driven endogenous lipogenesis appears not to be 
involved in the metabolic programming of basal-like breast carcinomas, which are 
often associated with an intrinsically aggressive clinical behavior, the activation of 
the FASN-driven lipogenic phenotype increases the aggressiveness of HER2-
positive breast carcinomas. Accordingly, the re-classification of HER2-positive 
breast tumors based on expression of FASN predicted a significantly inferior 
relapse-free survival and distant metastasis-free survival in the HER2+/FASN+ 
patient cohort. 
 
In a clinical scenario in which FASN-driven endogenous lipogenesis drives tumor 
cell proliferation and eventually metastasis, selective FASN inhibition may be a 
valuable therapeutic strategy for the HER2+ breast cancer subtype. Accordingly, 
HER2+/FASN+ breast cancer cells exhibited an exacerbated cytotoxic response to 
C75, a competitive and irreversible FASN inhibitor. The ability of CSC-like cellular 
states to survive and proliferate as floating spherical colonies under anchorage-
independent conditions is commonly regarded as an in vitro surrogate of the self-
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renewal and tumor-initiating potential exclusively possessed by CSCs. Our novel 
findings showing that C75-induced suppression of HER2-driven breast CSC 
populations specifically occurs via blockade of FASN-driven lipogenesis and 
therefore strongly suggest that the HER2-FASN lipogenic axis represents a 
powerful, but hitherto largely unexplored, target to eliminate treatment-refractory 
CSCs.  
 
New generations of FASN inhibitors are in development and one of them, the first 
oral, selective, potent, reversible FASN inhibitor TVB-2640, has recently entered 
clinical trials. Data from early-phase clinical trials have shown target engagement 
and prolonged stable disease when TVB-2640 was used as monotherapy (Arkenau 
et al., 2015; O’Farrell et al., 2015; Patel et al., 2015). In this scenario, the 
identification of pathophysiological mechanisms predictive of responsiveness to 
FASN inhibitors could assist in prioritizing anti-FASN drug discovery resources. Our 
current findings strongly suggest that HER2 overexpression may permit the 
delineation of a group of breast cancer patients that might benefit from therapeutic 
regimens containing FASN inhibitors, which could exert highly toxic effects against 
HER2-positive bulk tumor cells while at the same time restraining HER2-dependent 
CSC traits in tumor tissues.  
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MATERIALS AND METHODS 
 
Interpretation of immunohistochemical results. Immunohistochemical analyses 
of formalin-fixed tissue sections of paraffin-embedded invasive breast tumor 
biopsies (n=189) were performed as described (Menendez et al., 2006). The status 
of HER2 expression was analyzed using the anti-HER2 monoclonal antibody Ab-3 
(clone 3B5; Oncogene Science Inc., Manhasset, NY). HER2 immunohistochemistry 
(IHC) results were classified according to American Society of Clinical 
Oncology/College of American Pathologists (ASCO/CAP) guidelines, which includes 
the following categories: 0 = no immunostaining; 1+ = weak/incomplete membrane 
staining in less than 10% of tumor cells; 2+ = complete membrane staining that is 
either uniform or weak in at least 10% of all tumor cells; and 3+ = uniform, intense 
membrane staining in at least 30% of tumor cells. In the present study, HER2 
staining was considered positive when strong (3+) membranous staining was 
observed, whereas IHC 0 or 1+ were considered HER2 negative. Because IHC 2+ 
is an equivocal classification, in these cases HER2 expression was further 
evaluated with fluorescence in situ hybridization. 
 
Cytoplasmic intensities of FASN immunoreactivity were classified semi-
quantitatively into the four following categories: non-staining (0), weak (score 1+), 
moderate (score 2+), and strong (score 3+) in more than 30% of stained cells. 
When heterogeneous intensities of FASN immunoreactivity were observed within 
examined cases, the strongest intensity was adopted as the score of FASN 
expression. The staining intensity in normal breast tissue was used as an internal 
control. A score of 0−2+ was considered non-overexpression, whereas a score of 
3+ was considered overexpression.  
 
Survival analyses and Kaplan-Meier survival plots. Survival analyses and 
Kaplan-Meier survival plots were generated using the publicly accessible Kaplan 
Meier plotter (http://kmplot.com/analysis/), which can assess the effect of thousands 
of genes on survival using 4,142 breast cancer patients with a mean follow-up of 69 
months. The database is handled by a PostgreSQL server, which integrates gene 
expression and clinical data simultaneously. To analyze the prognostic value of a 
particular gene (e.g., FASN), the patient samples (e.g., HER2-positive) are split into 
two groups according to various quantile expressions of the proposed biomarker. A 
Kaplan-Meier survival plot compares the two patient cohorts, and the hazard ratio 
with 95% confidence intervals and logrank P value are calculated. 
 
Cell lines. HER2-overexpressing MCF-7/HER2 (clone 18) cells and their matched 
controls (empty vector-transfected) MCF-7/Neo cells were provided by Prof. Mien-
Chie Hung (The University of Texas MD Anderson Cancer Center, Houston, TX). 
HER2-overexpressing MCF10A/HER2 cells were generated and characterized as 
described in Menendez et al. (2015). Cells were screened periodically for 
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Mycoplasma contamination. 
 
FASN promoter luciferase assays. Cells were transfected with FuGENE 6 (Roche 
Biochemicals, Indianapolis, IN). Overnight serum-starved MCF10A and 
MCF10A/HER2 cells seeded into 24-well plates (5 × 104 cells/well) were transfected 
for 18 h in low-serum (0.1% horse serum, HS) medium with 300 ng/well of the 
pGL3-luciferase (Promega, Madison, WI) vector containing a luciferase reporter 
gene cloned downstream of an intact (FASN wtSREBP-BS-Luc) 178-bp FASN 
promoter fragment, and pRL-CMV (30 ng/well), which was used to correct for 
transfection efficiency. Transfected cells were washed and incubated with/without 
20 ng/mL EGF for a further 24 h. Luciferase activity in cell extracts was detected 
after 24 h using the Luciferase Assay System (Promega, Madison, WI) on the TD-
20/20 luminometer (Turner Designs, Sunnyvale, CA). The level of activation in 
FASN promoter-transfected cells was determined after normalization to the 
luciferase activity in cells transfected with equivalent amounts of the empty pGL3-
luciferase vector (∅-Luc) and the internal control plasmid pRL-CMV, which was 
taken as 1.0-fold. This control value was used to calculate the fold change in 
transcriptional activities of FASN promoter-transfected cells in response to 
treatments after normalization.  
 
Cell viability. Cell viability was determined using a modified MTT reduction assay 
(Cell Titer 96 Aqueous Non-Radioactive Cell Proliferation Assay, Promega). Briefly, 
cells in exponential growth were harvested by trypsinization, seeded at a 
concentration of 3 × 103 cells/200 µl/well into 96-well plates, and allowed to attach 
overnight. The medium was then replenished along with graded concentrations of 
C7, which was not renewed during the entire period of cell exposure. Following 
treatments (5–6 days), the plates were centrifuged at 200 g for 10 min and 
MTS/PMS solution was added to each well at a 1/5 volume. After incubation for 3 h 
at 37°C in the dark, the absorbance was measured at 490 nm using a multiwell 
plate reader. Control cells were subjected to the same procedure, but without C75. 
The cell viability effects from exposure to C75 were analyzed generating 
concentration–effect curves as a plot of the fraction of unaffected (surviving) cells 
versus drug concentration. Dose–response curves were plotted as a percentage of 
the control cell absorbance, which was obtained from control wells containing the 
C75 vehicle (DMSO) that were processed simultaneously. Cell viability was 
evaluated for each treatment as a percentage using the following equation: (A570 of 
treated sample/A570 of untreated sample) × 100. Breast cancer cell sensitivity to 
C75 was expressed in terms of the concentration of FASN inhibitor required for 50% 
(IC50) reduction of cell viability. Since the percentage of control absorbance was 
considered to be the surviving fraction of cells, the IC50 values were defined as the 
concentration of drug that produced 50% reduction in control absorbance (by 
interpolation). 
 
Soft Agar Colony Formation Assays. A bottom layer of 1 mL of 2× complete 
DMEM/F12 medium containing 0.7% agar and 10% HS was prepared in 35-mm 
multi-well cluster dishes. After the bottom layer solidified, 10,000 cells/dish were 
added in a 1-mL top layer of 2× complete DMEM/F12 medium containing C75 or 
vehicle in 0.35% agar and 10% HS as specified. All samples were prepared in 
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triplicate. After 2 weeks of incubation at 37°C in 5% CO2 and 95% air, colonies 
measuring ≥50 µm were counted after staining with nitroblue tetrazolium (Sigma, St 
Louis, MO) using a cell colony counter (Ommias 3600, Imaging Products 
International, Inc., Charley, VA). 
 
Cell cycle analysis. Adherent and detached cells were collected after trypsin 
treatment, washed in PBS and centrifuged at 1500 rpm. For DNA staining, the cells 
were washed again after harvesting and treated with RNAse A (0.2 mg/mL) in PBS 
at 37 oC for 20 min. Propidium iodide (20 µg/mL) was then added to the cell 
suspension and incubated for 30 min at room temperature protected from light. 
FACSDiva software (Becton Dickinson) was run for data acquisition using a 
FACScan flow cytometer and ModFit software for cell cycle analysis.  
 
Immunoblotting analyses of HER2. HER2 expression was assesed by western 
blotting using a monoclonal antibody against HER2 (Ab-3 clone, Oncogene 
Research Products, San Diego, CA) as described (Menendez et al. 2005a).  
 
Mammosphere culture and mammosphere-forming efficiency. Single cell 
suspensions (1000 cells/mL) were plated in 6-well tissue culture plates previously 
coated with poly-2-hydroxyethyl-methacrylate (Sigma, St. Louis, MO) to prevent cell 
attachment, in serum-free DMEM/F-12 supplemented with 1% L-glutamine, 1% 
penicillin/streptomycin, 2% B27 (Invitrogen, Carlsbad, CA), 20 ng/mL EGF (Sigma) 
and 20 ng/mL FGFb (Invitrogen). The medium was made semi-solid with 0.5% 
methylcellulose (R&D Systems, Minneapolis, MN) to prevent cell aggregation. 
Mammosphere-forming efficiency (MSFE) was calculated as the number of sphere-
like structures (diameter >50 µm) formed after 7 days divided by the original number 
of cells seeded, and expressed as a percentage.  
 
 
Statistical analysis. All observations were confirmed by at least three, independent 
experiments. Data are presented as means S.D. Student's t test (paired and 
unpaired) was used to evaluate the statistical significance of mean values. 
Statistical significance levels were P<0.05 (denoted as *) and P<0.005 (denoted as 
**). All Ps are two-tailed. 
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FIGURE LEGENDS 
 
Figure 1. Immunophenotypic classification of FASN-overexpression in HER2-
negative and HER2-positive invasive breast carcinomas.  
 
Figure 2. Kaplan-Meier Relapse-free survival curves of breast cancer 
subtypes stratified by low/high FASN gene expression.  
 
Figure 3. Kaplan-Meier Distant metastasis-free survival curves of breast 
cancer subtypes stratified by low/high FASN gene expression. 
 
Figure 4. Pharmacological blockade of FASN activity suppresses the HER2-
induced transforming phenotype in breast epithelial cells. Left. Transcriptional 
activities were expressed as relative (×-fold) changes in luciferase activity of FASN 
promoter-transfected MCF10A and MCF10/HER2 cells in response to treatments 
after normalization to pRL-CMV luciferase activity. Each experimental value 
represents the mean fold increase (columns) ± SD (bars) from at least three 
independent experiments measured in triplicate. Right. Soft-agar colony formation 
assay of MCF10A and MCF10A/HER2 cells cultured with/without C75. Each 
experimental value represents the mean colony number (columns) ± S. D. (bars) 
from at least three independent experiments measured in triplicate. 
 
Figure 5. HER2-overexpressing breast cancer cells are exquisitely sensitive to 
FASN inhibition-induced cell death. Top. Cell viability and IC50 values were 
determined using MTT reduction. Data summarize the mean±SD of five 
independent experiments measured in triplicate. Bottom. Cell cycle analysis of 
MCF-7/neo and MCF-7/HER2 cells by flow cytometry after 48 h with/without C75 
(10 µg/mL). Representative cell cycle profiles are shown for each cell line and 
treatment. Cell cycle analyses were repeated at least three times. Dashed boxes 
highlight the sub-G1 (apoptotic) cell populations in each cell line and treatment.   
 
Figure 6. HER2 gene-amplified but not HER2-negative breast cancer cells are 
sensitive to FASN inhibition-induced apoptosis. Top. HER2 protein expression 
in a panel of human breast cancer cell lines. Bottom. Fold-change in the C75-
induced percentage of sub-G1, G0/G1, S, and G2/M phases relative to untreated 
MDA-MB-231 and BT-474 cells (=1-fold in each phase). Cell cycle analyses were 
repeated at least three times. Standard deviations were less 0.1-fold for each 
experimental condition. 
 
Figure 7. Pharmacological blockade of FASN activity suppresses the HER2-
driven tumor-initiating capacity of CSCs. Mammosphere formation of MCF-7 and 
MCF-7/HER2 cells with/without C75 (left) or (-)-C75 (right). MSFE of vehicle-alone 
control cells was normalized to one in each cell line.   
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Table 1. Effects of C75 on the cell cycle distribution of MCF-7/HER2 and MCF-
7/Neo isogenic control cells.  
 
 
MCF-7/HER2 
 
Cell Cycle phase Untreated (%) C75 (%) 
 
Sub-G1 (apoptosis) 
 
17 
 
36 
G0/G1 63 39 
S 12 19 
G2/M 
 
8 6 
 
MCF-7/Neo 
 
Cell Cycle phase Untreated (%) C75 (%) 
 
Sub-G1 (apoptosis) 
 
13 
 
11 
G0/G1 55 38 
S 27 30 
G2/M 
 
  5 21 
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Figure 1 
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Figure 2  
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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Figure 7 
